Evaluation of bone mineral density measurement
Ringa V, Durieux P
Record ID 31995000092
Review of the literature concerning the technical aspects of BMD measurement, the epidemiology of osteoporosis, and the value of BMD measurement for the diagnosis of osteoporosis or as a screening tool. This study was conducted at the request of the French Social Security Department.
Authors' results and conclusions:
BMD measurement defines the extent of bone loss in osteoporosis and can be used as a baseline for evaluation of response to treatment. The main problem raised by osteopenia is its diagnosis at the time of menopause in order to prevent osteoporosis. BMD measurement appears to be themost reliable method, but would not be indicated if oestrogens were prescribed to all postmenopausal women. The exact correlation between a reduction of bone density and the fracture risk has not been defined.
BMD measurement cannot be recommended as a routine procedure for screening of osteoporosis in all postmenopausal women. BMD measurement is a method for evaluation of the efficacy of treatments for osteoporosis, but its value in the therapeutic management of the disease remains to be defined.
Other output or dissemination activity: Not covered by health insurers.
English language abstract:
An English language summary is available
- Absorptiometry, Photon
- Bone Density
- Estrogen Replacement Therapy
- Mass Screening
L'Agence Nationale d'Accreditation d'Evaluation en Santé
2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Agence Nationale pour le Developpement de l'Evaluation Medicale